vs
Apellis Pharmaceuticals, Inc.（APLS）与LSB INDUSTRIES, INC.（LXU）财务数据对比。点击上方公司名可切换其他公司
Apellis Pharmaceuticals, Inc.的季度营收约是LSB INDUSTRIES, INC.的1.2倍（$199.9M vs $169.5M），LSB INDUSTRIES, INC.净利率更高（11.6% vs -29.5%，领先41.1%），LSB INDUSTRIES, INC.同比增速更快（18.2% vs -5.9%），过去两年LSB INDUSTRIES, INC.的营收复合增速更高（10.0% vs 7.7%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
埃尔德里奇工业有限责任公司是一家总部位于美国迈阿密的控股公司，在纽约市、康涅狄格州格林威治、伦敦以及比弗利山均设有办事处，投资领域覆盖保险、资产管理、科技、体育、媒体、房地产与消费等多个行业。
APLS vs LXU — 直观对比
营收规模更大
APLS
是对方的1.2倍
$169.5M
营收增速更快
LXU
高出24.1%
-5.9%
净利率更高
LXU
高出41.1%
-29.5%
两年增速更快
LXU
近两年复合增速
7.7%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $169.5M |
| 净利润 | $-59.0M | $19.7M |
| 毛利率 | — | 21.1% |
| 营业利润率 | -25.6% | 13.7% |
| 净利率 | -29.5% | 11.6% |
| 营收同比 | -5.9% | 18.2% |
| 净利润同比 | -62.2% | — |
| 每股收益（稀释后） | $-0.40 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收APLSLXU
| Q1 26 | — | $169.5M | ||
| Q4 25 | $199.9M | $165.0M | ||
| Q3 25 | $458.6M | $155.4M | ||
| Q2 25 | $178.5M | $151.3M | ||
| Q1 25 | $166.8M | $143.4M | ||
| Q4 24 | $212.5M | $134.9M | ||
| Q3 24 | $196.8M | $109.2M | ||
| Q2 24 | $199.7M | $140.1M |
净利润APLSLXU
| Q1 26 | — | $19.7M | ||
| Q4 25 | $-59.0M | $16.1M | ||
| Q3 25 | $215.7M | $7.1M | ||
| Q2 25 | $-42.2M | $3.0M | ||
| Q1 25 | $-92.2M | $-1.6M | ||
| Q4 24 | $-36.4M | $-9.1M | ||
| Q3 24 | $-57.4M | $-25.4M | ||
| Q2 24 | $-37.7M | $9.6M |
毛利率APLSLXU
| Q1 26 | — | 21.1% | ||
| Q4 25 | — | 25.0% | ||
| Q3 25 | — | 16.4% | ||
| Q2 25 | — | 15.3% | ||
| Q1 25 | — | 10.0% | ||
| Q4 24 | — | 4.5% | ||
| Q3 24 | — | -7.3% | ||
| Q2 24 | — | 19.6% |
营业利润率APLSLXU
| Q1 26 | — | 13.7% | ||
| Q4 25 | -25.6% | 16.2% | ||
| Q3 25 | 48.7% | 10.1% | ||
| Q2 25 | -18.6% | 6.9% | ||
| Q1 25 | -50.0% | 3.1% | ||
| Q4 24 | -12.3% | -5.0% | ||
| Q3 24 | -24.0% | -22.4% | ||
| Q2 24 | -14.7% | 10.3% |
净利率APLSLXU
| Q1 26 | — | 11.6% | ||
| Q4 25 | -29.5% | 9.8% | ||
| Q3 25 | 47.0% | 4.6% | ||
| Q2 25 | -23.6% | 2.0% | ||
| Q1 25 | -55.3% | -1.1% | ||
| Q4 24 | -17.1% | -6.8% | ||
| Q3 24 | -29.2% | -23.2% | ||
| Q2 24 | -18.9% | 6.8% |
每股收益（稀释后）APLSLXU
| Q1 26 | — | — | ||
| Q4 25 | $-0.40 | $0.22 | ||
| Q3 25 | $1.67 | $0.10 | ||
| Q2 25 | $-0.33 | $0.04 | ||
| Q1 25 | $-0.74 | $-0.02 | ||
| Q4 24 | $-0.30 | $-0.13 | ||
| Q3 24 | $-0.46 | $-0.35 | ||
| Q2 24 | $-0.30 | $0.13 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | $181.7M |
| 总债务越低越好 | — | $770.0K |
| 股东权益账面价值 | $370.1M | $542.9M |
| 总资产 | $1.1B | $1.2B |
| 负债/权益比越低杠杆越低 | — | 0.00× |
8季度趋势，按日历期对齐
现金及短期投资APLSLXU
| Q1 26 | — | $181.7M | ||
| Q4 25 | $466.2M | $148.5M | ||
| Q3 25 | $479.2M | $152.0M | ||
| Q2 25 | $370.0M | $124.9M | ||
| Q1 25 | $358.4M | $163.5M | ||
| Q4 24 | $411.3M | $184.2M | ||
| Q3 24 | $396.9M | $199.3M | ||
| Q2 24 | $360.1M | $216.3M |
总债务APLSLXU
| Q1 26 | — | $770.0K | ||
| Q4 25 | — | $440.3M | ||
| Q3 25 | — | $447.6M | ||
| Q2 25 | — | $446.4M | ||
| Q1 25 | — | $478.2M | ||
| Q4 24 | — | $476.2M | ||
| Q3 24 | — | $476.0M | ||
| Q2 24 | — | $479.8M |
股东权益APLSLXU
| Q1 26 | — | $542.9M | ||
| Q4 25 | $370.1M | $520.0M | ||
| Q3 25 | $401.2M | $504.6M | ||
| Q2 25 | $156.3M | $495.8M | ||
| Q1 25 | $164.2M | $490.6M | ||
| Q4 24 | $228.5M | $491.6M | ||
| Q3 24 | $237.1M | $499.0M | ||
| Q2 24 | $264.3M | $522.8M |
总资产APLSLXU
| Q1 26 | — | $1.2B | ||
| Q4 25 | $1.1B | $1.2B | ||
| Q3 25 | $1.1B | $1.1B | ||
| Q2 25 | $821.4M | $1.1B | ||
| Q1 25 | $807.3M | $1.2B | ||
| Q4 24 | $885.1M | $1.2B | ||
| Q3 24 | $901.9M | $1.2B | ||
| Q2 24 | $904.5M | $1.2B |
负债/权益比APLSLXU
| Q1 26 | — | 0.00× | ||
| Q4 25 | — | 0.85× | ||
| Q3 25 | — | 0.89× | ||
| Q2 25 | — | 0.90× | ||
| Q1 25 | — | 0.97× | ||
| Q4 24 | — | 0.97× | ||
| Q3 24 | — | 0.95× | ||
| Q2 24 | — | 0.92× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | — |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | — |
| 自由现金流率自由现金流/营收 | -7.1% | — |
| 资本支出强度资本支出/营收 | 0.1% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $45.0M | — |
8季度趋势，按日历期对齐
经营现金流APLSLXU
| Q1 26 | — | — | ||
| Q4 25 | $-14.2M | $17.9M | ||
| Q3 25 | $108.5M | $52.6M | ||
| Q2 25 | $4.4M | $18.2M | ||
| Q1 25 | $-53.4M | $6.8M | ||
| Q4 24 | $19.4M | $4.0M | ||
| Q3 24 | $34.1M | $17.1M | ||
| Q2 24 | $-8.3M | $41.4M |
自由现金流APLSLXU
| Q1 26 | — | — | ||
| Q4 25 | $-14.3M | $-3.2M | ||
| Q3 25 | $108.3M | $35.6M | ||
| Q2 25 | $4.4M | $-315.0K | ||
| Q1 25 | $-53.4M | $-14.0M | ||
| Q4 24 | $19.3M | $-24.2M | ||
| Q3 24 | — | $-13.9M | ||
| Q2 24 | $-8.4M | $26.6M |
自由现金流率APLSLXU
| Q1 26 | — | — | ||
| Q4 25 | -7.1% | -1.9% | ||
| Q3 25 | 23.6% | 22.9% | ||
| Q2 25 | 2.5% | -0.2% | ||
| Q1 25 | -32.0% | -9.8% | ||
| Q4 24 | 9.1% | -18.0% | ||
| Q3 24 | — | -12.8% | ||
| Q2 24 | -4.2% | 19.0% |
资本支出强度APLSLXU
| Q1 26 | — | — | ||
| Q4 25 | 0.1% | 12.8% | ||
| Q3 25 | 0.0% | 10.9% | ||
| Q2 25 | 0.0% | 12.2% | ||
| Q1 25 | 0.0% | 14.5% | ||
| Q4 24 | 0.0% | 20.9% | ||
| Q3 24 | 0.0% | 28.4% | ||
| Q2 24 | 0.0% | 10.5% |
现金转化率APLSLXU
| Q1 26 | — | — | ||
| Q4 25 | — | 1.11× | ||
| Q3 25 | 0.50× | 7.39× | ||
| Q2 25 | — | 6.04× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 4.33× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
LXU
| AN & Nitric Acid | $75.3M | 44% |
| Urea ammonium nitrate (UAN) | $49.2M | 29% |
| Ammonia | $36.8M | 22% |
| Other | $8.2M | 5% |
